Healthcare

The progress of its pivotal Phase 3 trial and its partnering activity have framed the question of whether the next catalyst could spark a major re-rating.

A shift toward higher-value recurring revenue, set against a declining reported top line, has framed the question of whether the next commercial catalyst could spark a re-rating.

Record FY26 revenue and a sharp profit increase have raised the question of whether the market is underestimating this healthcare growth story.

The launch of CORIS and the trajectory of the trophonBusinesshave framed the question of whether the next catalyst could spark a major re-rating.

A FY26 result combining strong revenue growth with a large slate of new contracts has sharpened the question of whether the rally can keep running.

The failed takeover and the litigation around it have dominated the recent narrative, framing the question of what catalyst could next re-rate the shares.

•Revenuegrowth was supported by a recovery in both the industrial and healthcare glove and protective equipment segments.